Cantargia AB (publ) (FRA:7V3)

Market Cap	129.09M +254.3%
Revenue (ttm)	27.92M
Net Income	12.66M
EPS	0.05
Shares Out	n/a
PE Ratio	10.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,553
Open	0.5000
Previous Close	0.5610
Day's Range	0.5000 - 0.5000
52-Week Range	0.0635 - 0.5610
Beta	n/a
RSI	56.33
Earnings Date	Feb 20, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7V3

Financial Performance

Financial numbers in SEK